하지정맥류 치료 시장 예측(-2034년) : 제품 유형별, 치료법별, 최종사용자별, 지역별 세계 분석

According to Stratistics MRC, the Global Varicose Vein Treatment Market is accounted for $1.7 billion in 2026 and is expected to reach $3.3 billion by 2034 growing at a CAGR of 8.3% during the forecast period. Varicose vein treatment involves medical interventions aimed at addressing and alleviating the symptoms associated with varicose veins. Varicose veins are enlarged, twisted veins that commonly appear in the legs and result from weakened or damaged vein walls and valves. Lifestyle modifications, such as regular exercise, maintaining a healthy weight, and elevating the legs, can complement these medical interventions.

Market Dynamics:

Driver:

Rising patient awareness

Patients are now more proactive in consulting healthcare professionals for timely diagnosis and exploring available treatment modalities, ranging from lifestyle modifications to minimally invasive procedures. This heightened awareness extends to both the medical implications of untreated varicose veins, such as venous insufficiency and ulceration, and the aesthetic concerns associated with visible veins. Furthermore, the emphasis on preventive healthcare and early intervention has encouraged individuals to address venous issues promptly, fostering a positive impact on the varicose vein treatment market.

Restraint:

High cost

Diagnostic tests such as ultrasound imaging, which are necessary to assess the severity and underlying causes of varicose veins, may require specialized equipment, skilled healthcare professionals, and multiple sessions, leading to higher costs. Insurance coverage and reimbursement policies can also impact the affordability of varicose vein treatment. Moreover, the high cost of treatment can disproportionately affect individuals with lower incomes or inadequate insurance coverage, leading to disparities in healthcare access and outcomes, which is hampering this market size.

Opportunity:

Improving healthcare infrastructure

Advances in medical facilities, including the establishment of specialized vein clinics and the availability of state-of-the-art equipment, contribute to enhanced accessibility and quality of care for individuals with varicose veins. As these facilities integrate modern technologies and adhere to stringent medical standards, patients benefit from safer and more effective interventions. Additionally, the presence of skilled healthcare professionals specializing in venous disorders further strengthens the infrastructure, which is propelling this market's expansion.

Threat:

Lack of awareness

The lack of awareness contributes to delayed diagnosis and intervention, as patients may not seek medical advice until symptoms become severe. The absence of public education initiatives and the limited dissemination of information about varicose veins and available treatment options further exacerbate this challenge. Moreover, as a result, a substantial portion of the population remains uninformed about the importance of early intervention, thereby hindering this market.

Covid-19 Impact

The COVID-19 pandemic has negatively impacted the varicose vein treatment market in several ways. Lockdowns, restrictions on non-essential medical procedures, and the reallocation of healthcare resources to pandemic-related activities led to a significant decline in the number of elective procedures, including varicose vein treatments. Additionally, economic uncertainties and financial constraints during the pandemic resulted in reduced healthcare spending, thereby hampering this market size.

The venous closure products segment is expected to be the largest during the forecast period

The venous closure products segment is estimated to hold the largest share due to a range of medical devices designed to address venous insufficiency and varicose veins by closing or sealing affected veins. These products play a crucial role in minimally invasive treatments that aim to redirect blood flow to healthier veins. Further, these venous closure products contribute to the growing trend of minimally invasive interventions, providing patients with effective alternatives to traditional surgical approaches, which is boosting this segment's expansion.

The injection sclerotherapy segment is expected to have the highest CAGR during the forecast period

The injection sclerotherapy segment is anticipated to have highest CAGR during the forecast period. This technique involves injecting a sclerosing solution directly into the affected veins, causing them to collapse and eventually be absorbed by the body. It is particularly effective for smaller varicose veins and spider veins. Furthermore, injection sclerotherapy is often preferred for its simplicity, affordability, and outpatient nature, making it a popular choice for both patients and healthcare providers, driving this segment's expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to factors such as population aging, lifestyle changes, and increasing awareness. Key players such as Medtronic PLC, Alma Lasers Ltd., Teleflex Incorporated, and Boston Scientific are adopting minimally invasive procedures like endovenous laser treatment (EVLT), radiofrequency ablation (RFA), and injection sclerotherapy. In addition, as healthcare systems continue to evolve and the demand for effective, less-invasive interventions persists, this market is poised for further expansion.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period, owing to growing awareness of venous health. It reflects a trend toward minimally invasive procedures, such as endovenous laser treatment (EVLT), radiofrequency ablation (RFA), and injection sclerotherapy. Moreover, patients in Europe are increasingly seeking outpatient options with shorter recovery times, contributing to the popularity of these less invasive techniques, which are propelling this region's growth.

Key players in the market

Some of the key players in the Varicose Vein Treatment Market include Medtronic PLC, Dornier MedTech GmbH, Candela Medical, Won Tech Co. Ltd, Boston Scientific, Sciton Inc., El. En SpA Group, Alma Lasers Ltd, Teleflex Incorporated, AngioDynamics Inc., Eufoton SRL and Biolitec AG

Key Developments:

In December 2023, Teleflex Incorporated announced it was awarded the Peripheral Access purchasing agreement with Premier, Inc. Effective December 1st, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Teleflex's Peripheral Access products.

In November 2023, Medtronic plc announced that the United States Food and Drug Administration (FDA) have approved the Symplicity Spyral(TM) renal denervation (RDN) system, also known as the Symplicity(TM) blood pressure procedure, for the treatment of hypertension.

In November 2023, Boston Scientific Corporation announced the close of its acquisition of Relievant Medsystems Inc., a company that offers the only U.S. Food and Drug Administration-cleared Intracept(R) Intraosseous Nerve Ablation System, a therapy to treat vertebrogenic pain that is a form of chronic low back pain.

Products Covered:

• Venous Closure Products
• Ablation Devices
• Surgical Products
• Other Products

Treatment Types Covered:

• Surgical Ligation/Stripping
• Endovenous Ablation
• Injection Sclerotherapy
• Other Treatment Types

End Users Covered:

• Vein Clinics
• Ambulatory Care Unit
• Hospitals
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 End User Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Varicose Vein Treatment Market, By Product

• 5.1 Introduction
• 5.2 Venous Closure Products
• 5.3 Ablation Devices
  • 5.3.1 Radiofrequency Ablation Devices
  • 5.3.2 Laser Ablation Devices
• 5.4 Surgical Products
• 5.5 Other Products

6 Global Varicose Vein Treatment Market, By Treatment Type

• 6.1 Introduction
• 6.2 Surgical Ligation/Stripping
• 6.3 Endovenous Ablation
• 6.4 Injection Sclerotherapy
• 6.5 Other Treatment Types

7 Global Varicose Vein Treatment Market, By End User

• 7.1 Introduction
• 7.2 Vein Clinics
• 7.3 Ambulatory Care Unit
• 7.4 Hospitals
• 7.5 Other End Users

8 Global Varicose Vein Treatment Market, By Geography

• 8.1 Introduction
• 8.2 North America
  • 8.2.1 US
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 UK
  • 8.3.3 Italy
  • 8.3.4 France
  • 8.3.5 Spain
  • 8.3.6 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 Japan
  • 8.4.2 China
  • 8.4.3 India
  • 8.4.4 Australia
  • 8.4.5 New Zealand
  • 8.4.6 South Korea
  • 8.4.7 Rest of Asia Pacific
• 8.5 South America
  • 8.5.1 Argentina
  • 8.5.2 Brazil
  • 8.5.3 Chile
  • 8.5.4 Rest of South America
• 8.6 Middle East & Africa
  • 8.6.1 Saudi Arabia
  • 8.6.2 UAE
  • 8.6.3 Qatar
  • 8.6.4 South Africa
  • 8.6.5 Rest of Middle East & Africa

9 Key Developments

• 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 9.2 Acquisitions & Mergers
• 9.3 New Product Launch
• 9.4 Expansions
• 9.5 Other Key Strategies

10 Company Profiling

• 10.1 Medtronic PLC
• 10.2 Dornier MedTech GmbH
• 10.3 Candela Medical
• 10.4 Won Tech Co. Ltd
• 10.5 Boston Scientific
• 10.6 Sciton Inc.
• 10.7 El. En SpA Group
• 10.8 Alma Lasers Ltd
• 10.9 Teleflex Incorporated
• 10.10 AngioDynamics Inc.
• 10.11 Eufoton SRL
• 10.12 Biolitec AG